GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Intelligent Medicine Acquisition Corp (NAS:IQMDU) » Definitions » Tax Expense

IQMDU (Intelligent Medicine Acquisition) Tax Expense : $0.56 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Intelligent Medicine Acquisition Tax Expense?

Intelligent Medicine Acquisition's tax expense for the months ended in Dec. 2022 was $0.29 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2022 was $0.56 Mil.


Intelligent Medicine Acquisition Tax Expense Historical Data

The historical data trend for Intelligent Medicine Acquisition's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelligent Medicine Acquisition Tax Expense Chart

Intelligent Medicine Acquisition Annual Data
Trend Dec21 Dec22
Tax Expense
- 0.56

Intelligent Medicine Acquisition Quarterly Data
Feb21 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22
Tax Expense Get a 7-Day Free Trial - - 0.01 0.27 0.29

Intelligent Medicine Acquisition Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intelligent Medicine Acquisition  (NAS:IQMDU) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Intelligent Medicine Acquisition Tax Expense Related Terms

Thank you for viewing the detailed overview of Intelligent Medicine Acquisition's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Intelligent Medicine Acquisition Business Description

Traded in Other Exchanges
N/A
Address
9001 Burdette Road, Bethesda, MD, USA, 20817
Intelligent Medicine Acquisition Corp is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
Executives
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Joseph L Schocken director 2800 UNION SQUARE, 600 UNIVERSITY STREET, SEATTLE WA 98101
Kavita Patel director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jack Hidary director 3 PARK AVENUE, NEW YORK NY 10016
Gregory C Simon director, officer: CEO and CFO 9001 BURDETTE RD., BETHESDA MD 20817
Patience Marime-ball director 9001 BURDETTE RD., BETHESDA MD 20817
Intelligent Medicine Sponsor Llc 10 percent owner 9001 BURDETTE ROAD, BETHESDA MD 20817